Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLIS TechnologiesNZSE:BLT +4.35% Debt-to-Equity is 0.03 as of Mar. 2026, which is 50% below its 10-year median of 0.06. The stock has 8 warning signs investors should review. Among 962 Biotechnology companies, BLIS Technologies ranks better than 81.19% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BLIS Technologies's Debt-to-Equity or its related term are showing as below:
NZSE:BLT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.06 Max: 0.24
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of BLIS Technologies was 0.24. The lowest was 0.03. And the median was 0.06.
NZSE:BLT's Debt-to-Equity is ranked better than 81.19% of 962
companies
in the Biotechnology industry
Industry Median: 0.16
vs NZSE:BLT: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BLIS Technologies Debt-to-Equity Related Terms
BLIS Technologies Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BLIS Technologies's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:BLT vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, BLIS Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLIS Technologies Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLIS Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BLIS Technologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLIS Technologies (NZSE:BLT) has a Debt-to-Equity of 0.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BLIS Technologies and its competitors. This is 50% below median its historical median of 0.06. Over the past decade, BLIS Technologies' Debt-to-Equity has ranged from 0.03 to 0.24. According to the industry distribution chart, BLIS Technologies ranks #181 out of 962 companies in the Biotechnology industry, placing it in the top 18.8%.
Is BLIS Technologies' Debt-to-Equity too high?
BLIS Technologies' current Debt-to-Equity of 0.03 is 50% below median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.24. The Biotechnology industry median Debt-to-Equity is 0.16. BLIS Technologies' value of 0.03 is 81.3% below this industry median. Based on the distribution chart, BLIS Technologies ranks #181 out of 962 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does BLIS Technologies' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #181 out of 962 companies for Debt-to-Equity. This places BLIS Technologies in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. BLIS Technologies' value of 0.03 is 81.3% below this benchmark. Historically, BLIS Technologies' own Debt-to-Equity has ranged from 0.03 to 0.24 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 0.16, BLIS Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLIS Technologies's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BLIS Technologies and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLIS Technologies's current Debt-to-Equity is 0.03, which is 50% below median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Overvalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 20% above its estimated fair value. The current Debt-to-Equity is 0.03, which is 50% below median its 10-year median of 0.06 and 81.3% below the Biotechnology industry median of 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current Debt-to-Equity is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:BLT has been successfully added to your 
